New hope for kids with leukemia in Low-Income countries

NCT ID NCT04794296

Recruiting now Disease control Sponsor: French Africa Pediatric Oncology Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment plan for children with acute lymphoblastic leukemia (ALL) in low- and middle-income African countries. The plan uses stronger chemotherapy for high-risk cases and aims for an 85% remission rate. Researchers will track whether the drugs are available and if families can stick with the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (anthracycline, Endoxan, Methotrexate)
What this could lead to: If successful, this could provide a practical, effective treatment protocol for childhood leukemia in resource-limited settings, improving survival rates.
What could go wrong: This is an early feasibility study in low-income countries, so drug availability and adherence may be challenging. The 85% remission target is ambitious and may not be reached.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD ALL

Contacts and locations

Locations

CHU Donka 030 BP 554
RECRUITING

Conakry, Guinea
CHU de Treichville à ABIDJAN
RECRUITING

Abidjan, Côte d’Ivoire
Hôpital Aristide Le Dantec, Avenue Pasteur,
RECRUITING

Dakar, BP 3001, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.